ClinicalTrials.gg
RecruitingNCT07129382MECAPUpdated Nov 5, 2026

A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

A Phase 1/2 interventional study of CS32582 capsule(low dose) or matched placebo and CS32582 capsule(high dose) or matched placebo in Plaque Psoriasis, sponsored by Chipscreen Biosciences, Ltd.. Recruiting at 11 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
70th of 182
220 · median 171
Started
2025
with 35 others
Phase 1/2
11 of 206
2 open now
Primary completion
2027-09
later than 49 of 65 live
Registered
167th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 70th largest by planned enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 49 of the 65 other live ones, and was the 167th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment for 4 weeks.

Part 2 (Efficacy and Safety Assessment): A randomized, double-blind, placebo-controlled evaluation where approximately 200 adult patients with plaque psoriasis will undergo 12 weeks of treatment.

The resulting data will provide preliminary evidence on the safety and efficacy profile of CS32582, informing its subsequent development strategy.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily sign the form (ICF) after fully understanding the trial.
  • Age 18-70 years (inclusive) at consent, any gender
  • Clinically diagnosed with chronic plaque psoriasis, defined as disease duration ≥ 6 months at screening.
  • Stable plaque psoriasis at screening, defined as no significant flare-ups or morphological changes during the 6 months prior to screening (investigator-assessed).
  • Moderate-to-severe disease at screening/randomization: PASI≥12, sPGA≥3, and BSA≥10%;
  • Candidate for phototherapy or systemic therapy per investigator's judgment.
  • Women of and males: Agreement to use highly effective from consent until 30 days post-last dose.

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than plaque-type (e.g., erythrodermic, pustular, guttate, or drug-induced psoriasis) .
  • Presence of other skin conditions that in the judgement of the Investigator could interfere with study assessment.
  • Immune-mediated diseases requiring systemic therapy (e.g., inflammatory bowel disease), except NSAIDs.
  • History of severe drug allergies.
  • Major surgery within 2 months before randomization or planned during the study.
  • Drug/alcohol abuse within 6 months before screening.
  • Uncontrolled hypertension at screening (SBP >160 mmHg or DBP >100 mmHg).
  • Myocardial infarction, unstable angina, , stroke, PCI, or CABG within 6 months before screening.
  • Class III/IV heart failure at screening.
  • History of or lymphoproliferative disorders within 5 years (exceptions: basal cell carcinoma, localized squamous cell carcinoma, or cervical carcinoma in situ cured ≥1 year).
  • Prosthetic joint infection (unless prosthesis removed/replaced ≥2 months before randomization).
  • History of opportunistic infections (e.g., PJP, histoplasmosis, coccidioidomycosis).
  • Active/latent TB infection (positive IGRA without clinical manifestations).
  • Herpes infection:a) Active herpes zoster/simplex (HSV-1/2) at screening;b) History of severe herpes (disseminated disease, multidermatomal HSV, encephalitis, ophthalmic herpes, or recurrent zoster [≥2 episodes in 2 years]).
  • History of severe bacterial, fungal, or viral infection requiring hospitalization for IV antibiotic or antiviral administration within 2 months before randomization.
  • History of administration within 2 months before randomization or plans to receive a live vaccine during the study period.
  • Evidence of active infection and/or febrile illness requiring systemic anti-infective therapy within 2 weeks before randomization.
  • Abnormal virology at screening:

    • (+) or HBcAb(+) with detectable HBV-DNA
    • Ab(+) with detectable HCV-RNA
    • History of infection or HIV Ab(+)
    • Treponema pallidum Ab(+) with positive RPR/TRUST
  • Prior use of TYK2 inhibitors (e.g., deucravacitinib).
  • Use of any of the following therapeutic agents within 6 months before randomization:

    • IL-12/23, IL-17, or IL-23 inhibitors (ustekinumab, secukinumab, tildrakizumab, ixekizumab, guselkumab)
    • Rituximab or other B-cell depleting agents
    • Leflunomide
  • Use of any of the following therapeutic agents within 3 months before randomization: Integrin pathway modulators (natalizumab) or B/T-cell modulators (alemtuzumab, abatacept, vedolizumab).
  • Use of TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab) within 2 months before randomization.
  • Any biologic psoriasis therapy within 3 months or 5 half-lives (whichever longer) before randomization.
  • Use of systemic non-biologic psoriasis agents and/or any systemic within 4 weeks before randomization, including but not limited to: apremilast, methotrexate, azathioprine, cyclosporine, JAK inhibitors, 6-thioguanine, mercaptopurine, mycophenolate, hydroxyurea, tacrolimus, oral/injectable , retinoids, calcitriol/analogs, psoralen, sulfasalazine, fumarates).
  • Use of Lithium, antimalarials, or intramuscular gold preparations within 4 weeks before randomization.
  • Use of any botanical agents for the treatment of psoriasis or other immune disorders within 4 weeks before randomization, including herbal supplements or traditional Chinese medicines derived from plants, minerals, or animals.
  • Received phototherapy within 4 weeks before randomization.
  • Use of medicated shampoos and/or body washes within 2 weeks before randomization, including but not limited to products containing: corticosteroids, coal tar, >3% salicylic acid, vitamin D3 analogs.
  • Use of any topical agents that may affect psoriasis symptoms within 2 weeks before randomization.
  • Received any therapy within 30 days or 5 half-lives (whichever is longer) before randomization, OR current participation in other trial.
  • Laboratory values meeting any of the following criteria during screening or before randomization:

    • Liver: /AST ≥3×; total >2×ULN
    • Hematology: WBC \<3.0×10⁹/L (3000/mm³); ANC \<1.0×10⁹/L (1000/mm³); lymphocyte count \<0.5×10⁹/L (500/mm³); \<100×10⁹/L (100,000/mm³); \<9.0 g/dL (90 g/L)
    • Renal: \<60 mL/min/1.73m² (CKD-EPI equation)
  • Pregnant or lactating women.
  • Any condition deemed unsuitable by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Part 1:Low dose CS32582

    The patient received low-dose CS32582 capsules BID or placebo for 4 weeks

    Drug: CS32582 capsule(low dose) or matched placebo

  • Experimental
    Part 1:Hgh dose CS32582

    The patient received high-dose CS32582 capsules BID or placebo for 4 weeks

    Drug: CS32582 capsule(high dose) or matched placebo

  • Experimental
    Part 2:Low dose CS32582

    The patient received low-dose CS32582 capsules BID or placebo for 12 weeks

    Drug: CS32582 capsule(low dose)

  • Experimental
    Part 2:Medium dose CS32582

    The patient received medium-dose CS32582 capsules BID or placebo for 12 weeks

    Drug: CS32582 capsule(medium dose)

  • Experimental
    Part 2:High dose CS32582

    The patient received high-dose CS32582 capsules BID or placebo for 12 weeks

    Drug: CS32582 capsule(high dose)

Interventions

  • DrugCS32582 capsule(low dose) or matched placebo

    CS32582 capsule(low dose) or matched placebo,4 weeks

  • DrugCS32582 capsule(high dose) or matched placebo

    CS32582 capsule(high dose) or matched placebo,4 weeks

  • DrugCS32582 capsule(low dose)

    CS32582 capsule(low dose),12 weeks

  • DrugCS32582 capsule(medium dose)

    CS32582 capsule(medium dose),12 weeks

  • DrugCS32582 capsule(high dose)

    CS32582 capsule(high dose),12 weeks

06

What researchers measure

Primary outcomes

  1. Part 1:Incidence and Severity of Adverse Events (AEs)

    Time frame: 5 weeks

  2. Part 2:Proportion of patients achieved Psoriasis Area Severity Index (PASI) 75 at Week 12

    Psoriasis Area and Severity Index (PASI) scores range from 0 to 72, with higher scores indicating more severe disease activity. PASI 75 is defined as the proportion of patients achieving ≥75% reduction in PASI score from baseline.

    Time frame: Week 12

Secondary outcomes

  1. Part 1: Changes from baseline in PASI

    Psoriasis Area and Severity Index (PASI) scores range from 0 to 72, with higher scores indicating more severe disease activity.

    Time frame: Week 4

  2. Part 1: Changes from baseline in sPGA

    Static Physician's Global Assessment (sPGA) is an average assessment of all psoriatic lesions, with scores ranging from 0 (indicating clear) to 5 (indicating severe).

    Time frame: Week 4

  3. Part 1: Changes from baseline in BSA

    Body Surface Area (BSA) scores range from 0% (indicating absence of lesions) to 100% (indicating total body surface involvement), with higher scores correlating to greater disease severity.

    Time frame: Week 4

  4. Part 1: Changes from baseline in DLQI

    Dermatology Life Quality Index(DLQI) total score ranges from 0 (indicating no impairment in quality of life) to 30 (indicating maximum impairment in quality of life).

    Time frame: Week 4

  5. Part 1:Proportion of patients achieving PASI 50/75/90/100

    Psoriasis Area and Severity Index (PASI) scores range from 0 to 72, with higher scores indicating more severe disease activity. PASI 50 is defined as the proportion of patients achieving ≥50% reduction in PASI score from baseline. PASI 75 is defined as the proportion of patients achieving ≥75% reduction in PASI score from baseline.PASI 90 is defined as the proportion of patients achieving ≥90% reduction in PASI score from baseline.PASI 100 is defined as the proportion of patients achieving ≥100% reduction in PASI score from baseline.

    Time frame: Week 4

  6. Part 2:Incidence and Severity of Adverse Events (AEs)

    Time frame: 16 weeks

  7. Part 2:Proportion of patients achieving PASI 75

    Psoriasis Area and Severity Index (PASI) scores range from 0 to 72, with higher scores indicating more severe disease activity. PASI 75 is defined as the proportion of patients achieving ≥75% reduction in PASI score from baseline.

    Time frame: Week 4 and 8

  8. Part 2:Proportion of patients achieving PASI 50/90/100

    Psoriasis Area and Severity Index (PASI) scores range from 0 to 72, with higher scores indicating more severe disease activity. PASI 50 is defined as the proportion of patients achieving ≥50% reduction in PASI score from baseline. PASI 90 is defined as the proportion of patients achieving ≥90% reduction in PASI score from baseline.PASI 100 is defined as the proportion of patients achieving ≥100% reduction in PASI score from baseline.

    Time frame: Week 4,8 and 12

  9. Part 2:Proportion of patients achieving: (a) sPGA score of 0 or 1 with ≥2-point reduction from baseline (b) sPGA clearance (score 0) (c) Disease remission

    Time frame: Week 4,8 and 12

  10. Part 2: Changes from baseline in PASI

    Psoriasis Area and Severity Index (PASI) scores range from 0 to 72, with higher scores indicating more severe disease activity.

    Time frame: Week 4,8 and 12

  11. Part 2: Changes from baseline in BSA

    Body Surface Area (BSA) scores range from 0% (indicating absence of lesions) to 100% (indicating total body surface involvement), with higher scores correlating to greater disease severity.

    Time frame: Week 4,8 and 12

  12. Part 2: Changes from baseline in sPGA

    Static Physician's Global Assessment (sPGA) is an average assessment of all psoriatic lesions, with scores ranging from 0 (indicating clear) to 5 (indicating severe).

    Time frame: Week 4,8 and 12

  13. Part 2: Changes from baseline in DLQI

    Dermatology Life Quality Index(DLQI) total score ranges from 0 (indicating no impairment in quality of life) to 30 (indicating maximum impairment in quality of life).

    Time frame: Week 4,8 and 12

  14. Pharmacokinetic parameters - Area Under the Curve(AUC)

    Time frame: Day 1~Day 85

  15. Pharmacokinetic parameters - Peak Plasma Concentration (Cmax)

    Time frame: Day 1~Day 85

07

Study locations

1 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 15 phase 1/2 interventional studies under Psoriasis, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 19, 2025
StartActual
Sep 8, 2025
Primary completionEst.
Sep 18, 2027
CompletionEst.
Sep 18, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07129382
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Sep 8, 2025
Primary completion
Sep 18, 2027 (estimated)
Completion
Sep 18, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Jianzhong Zhang
Contact
rmzjz@126.com
18001315877

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion